Moderate hemophilia A

The Hospital for Sick Children

Wayne State University

ROCTAVIAN: FDA approved

treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test

ASC Therapeutics — PHASE1, PHASE2

Hoffmann-La Roche — PHASE4

Hemlibra: FDA approved

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors

Eloctate: FDA approved

Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

TRETTEN: FDA approved

Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Corifact: FDA approved

For the routine prophylactic treatment of congenital factor XIII deficiency